Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Merrill Lynch on Celgene’s $2.9 Billion Acquisition of Pharmion


NEW YORK, NY, November 19, 2007 — Celgene Corporation and Pharmion Corporation announced the signing of a definitive merger agreement under which Celgene will acquire Pharmion for approximately $2.9 billion. Covington & Burling LLP advised Merrill Lynch, Pierce, Fenner & Smith Incorporated, financial advisor to Celgene, on the transaction, which is expected to close by the end of the second quarter of 2008.

Celgene is a multinational integrated biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immunological diseases through regulation of genomic and proteomic targets. Pharmion is a leading global oncology company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the United States, Europe, and additional international markets. Merrill Lynch is one of the world's leading wealth management, capital markets and advisory companies, with offices in 38 countries and territories and total client assets of approximately $1.7 trillion.

The Covington corporate team, based in New York, included partner Jack Bodner and associate Andrew Ment.

Share this article: